Physician profile
Naomi N Fukuda
NPI 1629471834
$11,182.90
in general payments reported to CMS, 2019-2025
19 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 99% of Medical-Surgical (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $972 · 2022: $2,240 · 2023: $2,463 · 2024: $3,153 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,660 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,660.18 |
| Education | $310.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,502.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $2,063.46 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $1,954.63 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $1,519.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $974.47 | 2021-2025 | |
| Mannkind Corporation | $408.63 | 2022-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.09 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Corcept Therapeutics | $241.20 | 2023-2025 | Korlym |
| Insulet Corporation | $240.66 | 2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $208.37 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $146.21 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $140.52 | 2021-2023 | Farxiga |
| Esperion Therapeutics, INC. | $134.33 | 2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $103.76 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $50.40 | 2025 | Tepezza, Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $38.60 | 2024 | Ilet Bionic Pancreas |
| Abbvie INC. | $23.54 | 2021 | |
| Averitas Pharma INC. | $23.02 | 2025 | Qutenza |
| Medtronic, INC. | $14.80 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Fukuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.